Loading...

SMSPHARMA SMS Pharmaceuticals Ltd Earnings Reports Announcement

SMS

SMSP

SMS Pharmaceuticals Ltd

(SMSPHARMA)

2026 Announcement

Regulatory Update

Rights issue proceeds monit...

Unaudited quarterly results

Investor Presentation

Newspaper publication

Fund Utilisation Deviation

Quarterly Results

Board Meeting Outcome

Results approval

Share transfer status

Regulatory Compliance

Trading window closure

Rights issue subscription

Wholly Owned Subsidiary

USFDA Inspection

Upgrade & Outlook

Earnings Call Transcript

Utilization of Proceeds

Regulatory Compliance

SEBI SAST Disclosure

Conference Call Audio

Strong Q2 Results

Investor Presentation

Financial Results Publication

No Fund Deviation

Financial Results

Financial Results Approved

Trading Approval Received

Regulatory Disclosure

Share Pledge Release

Investor Call Scheduled

Transfer Requests Update

Insider Trading Disclosure

Board Meeting Notice

Share Pledge Update

Share Transfer Update

Compliance Certificate

Market Clarification

Warrants Conversion

AGM Notice Dispatch

Annual Report Update

Annual General Meeting

Inspection Report Received

Investor Education Campaign

Monitoring Agency Report

Q1 Results Published

Investor Presentation

Q1 Financial Results

Fund Usage Update

Share Transfer Window

Share Transfer Notice

Compliance Certificate

IEPF Transfer Reminder

Management Change

NCLT Petition Filed

USFDA Inspection Success

Trading Approval Received

Earnings Call Transcript

Investor Call Summary

Financial Results Publication

Strong Financial Growth

Investor Presentation

Inspection Report Received

Secretarial Compliance

Fund Utilization Report

Board's Response

Management Change

Investor Conference Call

Monitoring Report

WHO Approval Received

Compliance Certificate

Equity Shares Allotted

Income Tax Notice

USFDA Inspection Success

Regulatory Fine Imposed

Plant Visit Announcement

Financial Results Announcement

Investor Presentation

Financial Results Update

Monitoring Agency Report

Materiality Determined

Compliance Issue Update

Updated Insider Code

Fund Utilization Update

Compliance Certificate

Regulatory Fine Imposed

Earnings Call Summary

Investor Meet Update

Investor Presentation

Financial Results Q2

Monitoring Report

Financial Results Published

Fund Utilisation Update

Investor Call Announcement

New Subsidiary Created

Regulatory Compliance

Director Appointments

EDQM Certification

AGM Notice Dispatch

Annual General Meeting

KYC Update Reminder

Earnings Call Transcript

Audio Recording Release

Financial Results Announcement

Investor Presentation

Monitoring Agency Report Su...

Financial Results Publication

Funds Utilization Deviation

Investor Conference Call

Compliance Certificate Subm...

Shareholder Dividend Reminder

Investor Conference

Investor Presentation

Financial Results

Financial Results Advertise...

Related Party Transactions ...

Compliance Submission

Management Changes

Deviation in Fund Utilization

Investor Conference Call

Monitoring Report Submission

Compliance Certificate Subm...

Compliance Certificate Subm...

Regulatory Compliance

Allotment of Warrants

Completion of Inspection

Conference Call Outcome

Advertisement Confirmation ...

Reminder Letter to Physical...

Audio Recording Availability

Newspaper Publication

Financial Results

Investor Presentation

Amendment of Code of Practices

Approval of financial resul...

Investor Conference Call

Certificate Submission

Conference Call Transcript

Conference Call Recording

Investor Presentation

Financial Results Press Rel...

Update on pledge of shares ...

Investor Conference Call

Certificate Submission

SMS Pharmaceuticals announc...

Publication of AGM details

Earnings Releases

Audio Recording of Conferen...

Financial Statements

Financial Statements

Financial Statements

Financial Statements

Debt-Equity Swaps

Management Changes

Financial Statements

Management Changes

Filing of Annual Report

Analyst/Investor Meet - Out...

Financial Results

Financial Results Publication

Management Changes

Investor Meetings

External Links:

Data:

SMS Pharmaceuticals reports robust Q3 FY26 results with double-digit revenue growth, margin expansion, and a strong capex push; maintains ~20% FY26 revenue growth and >20% EBITDA margin, with a solid R&D pipeline.

AI Assistant

SMS Pharmaceuticals Ltd

2026

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.